½ÃÀ庸°í¼­
»óǰÄÚµå
1598502

°æÄ«Å×ÅÍ »öÀü ¹× Æó»ö ±â±â ½ÃÀå : Á¦Ç°, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Transcatheter Embolization & Occlusion Device Market by Product (Accessories, Embolization Coils, Embolization Particles), Application (Neurology, Oncology, Peripheral Vascular Disease), End User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 186 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

°æÄ«Å×ÅÍ »öÀü ¹× Æó»ö ±â±â ½ÃÀåÀº 2023³â 52¾ï 9,000¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2024³â¿¡´Â 59¾ï 4,000¸¸ ´Þ·¯·Î ¿¬Æò±Õ 12.76% ¼ºÀåÇÏ¿© 2030³â¿¡´Â 122¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

°æÄ«Å×ÅÍ »öÀü ¹× Æó»ö ±â±â´Â ÁßÀçÀû ¿µ»óÀÇÇÐÀÇ ÇʼöÀûÀÎ ±¸¼º¿ä¼Ò·Î, ÃâÇ÷À» ¿¹¹æÇÏ°í µ¿¸Æ·ù¸¦ °ü¸®Çϸç Á¾¾ç¿¡ ´ëÇÑ Ç÷¾× °ø±ÞÀ» ÁÙÀ̱â À§ÇØ Ç÷°üÀ» ¸·µµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù. ÀÌ ±â±â´Â ÃÖ¼Òħ½À ¼ö¼ú¿¡ ÇʼöÀûÀÌ¸ç °³º¹ ¼ö¼ú¿¡ ´ëÇÑ ´ë¾ÈÀ» Á¦°øÇÔÀ¸·Î½á ȸº¹ ½Ã°£°ú °ü·Ã À§ÇèÀ» ÁÙ¿©ÁÝ´Ï´Ù. ½ÃÀåÀÇ ¿ëµµ´Â Á¾¾ç °ü¸®¸¦ À§ÇÑ Á¾¾çÇÐ, ¼ÒÈ­°ü ÃâÇ÷À» À§ÇÑ ¼ÒÈ­±âÇÐ, Àü¸³¼± ÀÌ»ó ÃâÇ÷À» À§ÇÑ ºñ´¢±âÇÐ µî ´Ù¾çÇÑ ÃÖÁ¾ ¿ëµµ¿¡ °ÉÃÄ ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ¿äÀÎÀ¸·Î´Â ¾Ï ¹× Ç÷°ü ÁúȯÀÇ Áõ°¡, Ä«Å×ÅÍ ±â¼úÀÇ ¹ßÀü, ÃÖ¼Òħ½À ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. »õ·Î¿î ºñÁî´Ï½º ±âȸ´Â Á¤È®µµ¿Í Ä¡·á °á°ú¸¦ Çâ»ó½ÃŰ´Â »öÀü ±â±â¿Í ¿µ»ó ±â¼úÀÇ ÅëÇÕ, Ä¡·á È¿°ú Çâ»ó°ú ºÎÀÛ¿ë °¨¼Ò¸¦ ¾à¼ÓÇÏ´Â ¾à¹° ¿ëÃ⼺ »öÀüÁ¦ ¹× »ýºÐÇØ¼º »öÀüÁ¦ÀÇ »ç¿ë È®´ë¿¡ ÀÖ½À´Ï´Ù. ±×·¯³ª ÷´Ü ÀåºñÀÇ °í°¡, Àü¹® ±â¼úÀÌ ÇÊ¿äÇÑ º¹ÀâÇÑ ½Ã¼ú, ÇÕº´ÁõÀ¸·Î À̾îÁú ¼ö ÀÖ´Â ºñÇ¥Àû »öÀüÁõÀÇ ÀáÀçÀû À§Ç輺 µî ¿©·¯ °¡Áö ¹®Á¦Á¡ÀÌ ÀÖ½À´Ï´Ù. ¾ö°ÝÇÑ ±ÔÁ¦ ±âÁØÀº ½ÃÀå ¿ªÇÐÀ» ´õ¿í Á¦ÇÑÇÏ¿© Á¦Ç° ½ÂÀÎ ¹× Ãâ½Ã ¼Óµµ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ÀÌ·¯ÇÑ Á¦¾à¿¡µµ ºÒ±¸Çϰí, Çõ½ÅÀÇ ±âȸ°¡ ¹«¸£ÀͰí ÀÖ´Â ºÐ¾ß¿¡´Â ¿ì¼öÇÑ ¼º´ÉÀ» Á¦°øÇÏ´Â Â÷¼¼´ë »ýüÀûÇÕ¼º Àç·áÀÇ °³¹ß, ´õ ³ªÀº Ž»ö ¹× »ðÀÔÀ» À§ÇÑ ÀΰøÁö´É µµ±¸ µîÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ȯÀÚº° ¸ÂÃãÈ­¿¡ ÃÊÁ¡À» ¸ÂÃá ¿¬±¸·Î Ä¡·á ÇÁ·ÎÅäÄÝÀ» °³Àκ° Çʿ信 ¸Â°Ô ¸ÂÃãÈ­ÇÏ¿© Ä¡·á È¿°ú¸¦ ±Ø´ëÈ­ÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëµË´Ï´Ù. ½ÅÈï±¹ÀÇ ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÆÄ¾ÇÇÏ´Â °ÍÀº ½ÃÀå ħÅõ¿Í È®Àå¿¡ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ±â¼ú ¹ßÀü°ú ÇコÄɾî ÀÎÇÁ¶ó ÅõÀÚ È®´ë¿¡ µû¸¥ ±âȸ·Î ÀÎÇØ ÀÌ ½ÃÀåÀº ¿ªµ¿ÀûÀÎ Àü¸ÁÀ» Á¦½ÃÇϰí ÀÖÀ¸¸ç, ±â¾÷µéÀº ÀÌ·¯ÇÑ Á¦¾à¿¡ ´ëÀÀÇϰí Àü·«Àû Á¦ÈÞ ¹× ÆÄÆ®³Ê½Ê, R&D ÅõÀÚ, ¾ö°ÝÇÑ ½ÃÀå ºÐ¼®À» ÅëÇØ ÁøÈ­ÇÏ´Â ¼ÒºñÀÚ ¼ö¿ä¿¡ ´ëÀÀÇÔÀ¸·Î½á ¼ºÀåÀÇ ¹ßÆÇÀ» ¸¶·ÃÇÒ ¼ö ÀÖ½À´Ï´Ù. ¼ºÀåÀÇ ¹ßÆÇÀ» ¸¶·ÃÇϰí ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ[2023] 52¾ï 9,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ[2024] 59¾ï 4,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ[2030] 122¾ï 8,000¸¸ ´Þ·¯
CAGR(%) 12.76%

½ÃÀå ¿ªÇÐ : ºü¸£°Ô ÁøÈ­ÇÏ´Â °æÄ«Å×ÅÍ »öÀü ¹× Æó»ö ±â±â ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

°æÄ«Å×ÅÍ »öÀü ¹× Æó»ö ±â±â ½ÃÀåÀº ¼ö¿ä¿Í °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ» ÅëÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«ÀûÀÎ ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ÃËÁø¿äÀÎ
    • ÃÖ¼Òħ½À ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
    • ´ë»ó Áúȯ ºÎ´ã Áõ°¡
    • ½ÉÇ÷°üÁúȯ ¹× È£Èí±âÁúȯ ¹ß»ý·ü ±ÞÁõ
  • ½ÃÀå ¾ïÁ¦¿äÀÎ
    • Á¦Ç°ÀÇ ³ôÀº ºñ¿ë
  • ½ÃÀå ±âȸ
    • È¿À²¼ºÀ» ³ôÀÎ ÀåºñÀÇ ±â¼úÀû Áøº¸
    • TEO Àåºñ äÅà Áõ°¡
  • ½ÃÀå °úÁ¦
    • Á¦Ç°È­¸¦ À§ÇÑ ¾ö°ÝÇÑ ±ÔÁ¦ ÀýÂ÷

Porter's Five Forces : °æÄ«Å×ÅÍ »öÀü ¹× Æó»ö ±â±â ½ÃÀåÀ» Ž»öÇÏ´Â Àü·«Àû µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲÀÇ °æÀï »óȲÀ» ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®¸¦ ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : °æÄ«Å×ÅÍ »öÀü ¹× Æó»ö ±â±â ½ÃÀå¿¡¼­ÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº °æÄ«Å×ÅÍ »öÀü ¹× Æó»ö ±â±â ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : °æÄ«Å×ÅÍ »öÀü ¹× Æó»ö ±â±â ½ÃÀåÀÇ °æÀï »óȲ ÆÄ¾Ç

°æÄ«Å×ÅÍ »öÀü ¹× Æó»ö ±â±â ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÀλçÀÌÆ®¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : °æÄ«Å×ÅÍ »öÀü ¹× Æó»ö ±â±â ½ÃÀå¿¡¼­ÀÇ °ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â °æÄ«Å×ÅÍ »öÀü ¹× Æó»ö ±â±â ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î º¥´õ¸¦ Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

°æÄ«Å×ÅÍ »öÀü ¹× Æó»ö ±â±â ½ÃÀå¿¡¼­ ¼º°øÇϱâ À§ÇÑ Àü·« ºÐ¼® ¹× ±ÇÀå »çÇ×

°æÄ«Å×ÅÍ »öÀü ¹× Æó»ö ±â±â ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖµµ·Ï ÁغñÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï »óȲÀ» öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ÇâÈÄ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº ¾îµðÀΰ¡?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õÀÇ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå °æÄ«Å×ÅÍ »öÀü ¹× Æó»ö ±â±â ½ÃÀå : Á¦Ç°º°

  • ¾×¼¼¼­¸®
  • »öÀü ÄÚÀÏ
  • »öÀüÀÔÀÚ
  • Ç÷·ù Àüȯ±â µð¹ÙÀ̽º
  • ¾×ü »öÀü

Á¦7Àå °æÄ«Å×ÅÍ »öÀü ¹× Æó»ö ±â±â ½ÃÀå : ¿ëµµº°

  • ½Å°æÇÐ
  • Á¾¾çÇÐ
  • ¸»ÃÊÇ÷°ü Áúȯ
  • ºñ´¢±â°ú

Á¦8Àå °æÄ«Å×ÅÍ »öÀü ¹× Æó»ö ±â±â ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
  • Ŭ¸®´Ð
  • º´¿ø

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ °æÄ«Å×ÅÍ »öÀü ¹× Æó»ö ±â±â ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °æÄ«Å×ÅÍ »öÀü ¹× Æó»ö ±â±â ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ °æÄ«Å×ÅÍ »öÀü ¹× Æó»ö ±â±â ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®
  • ¿µ±¹

Á¦12Àå °æÀï »óȲ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • Abbott Laboratories
  • Agilent Technologies Inc
  • Artio Medical, Inc.
  • Becton Dickinson and Company
  • Boston Scientific Corporation
  • Edwards Lifesciences Corporation
  • Integer Holdings Corporation
  • Koninklijke Philips N.V.
  • Medtronic PLC
  • Merit Medical Systems, Inc.
  • Penumbra, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Siemens AG
  • Stryker Corporation
  • Terumo Corporation
  • The 3M Company
ksm 24.11.29

The Transcatheter Embolization & Occlusion Device Market was valued at USD 5.29 billion in 2023, expected to reach USD 5.94 billion in 2024, and is projected to grow at a CAGR of 12.76%, to USD 12.28 billion by 2030.

Transcatheter Embolization and Occlusion Devices are integral components of interventional radiology, designed to block blood vessels to prevent bleeding, manage aneurysms, or reduce blood supply to tumors. These devices are crucial for minimally invasive procedures, offering alternatives to open surgeries thereby reducing recovery time and associated risks. The market application spans various end-uses, including oncology for tumor management, gastroenterology for gastrointestinal bleeds, and urology for abnormal prostate bleeding, among others. Key factors influencing market growth include rising incidences of cancer and vascular diseases, advances in catheter technology, and increasing demand for minimally invasive surgical procedures. Emerging opportunities lie in the integration of imaging technology with embolization devices that improve precision and outcomes, and the expanding utilization of drug-eluting and biodegradable embolization agents, which promises enhanced therapeutic effectiveness and reduced side effects. However, the market faces challenges such as high costs of advanced devices, complexity in procedures necessitating specialized skills, and potential risks of non-target embolization leading to complications. Regulatory stringent standards further constrain market dynamics, often impacting the speed of product approvals and launches. Despite these limitations, areas ripe for innovation include the development of next-generation bio-compatible materials offering superior performance, and artificial intelligence tools for better navigation and placement. Research focusing on patient-specific customization of devices is anticipated to tailor treatment protocols down to individual needs, maximizing efficacy. Understanding the need for cost-effective solutions in emerging economies could prove pivotal for market penetration and expansion. The market, ripe with opportunities surrounding technological advancements and growing healthcare infrastructure investment, poses a dynamic landscape, with businesses poised for growth by addressing these constraints and leveraging strategic alliances or partnerships, R&D investments, and rigorous market analysis to navigate evolving consumer demands.

KEY MARKET STATISTICS
Base Year [2023] USD 5.29 billion
Estimated Year [2024] USD 5.94 billion
Forecast Year [2030] USD 12.28 billion
CAGR (%) 12.76%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Transcatheter Embolization & Occlusion Device Market

The Transcatheter Embolization & Occlusion Device Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing demand for minimally invasive surgeries
    • Increased burden of targeted diseases
    • Surge in incidence of cardiovascular diseases and respiratory disorders
  • Market Restraints
    • High cost of products
  • Market Opportunities
    • Technological advances in the devices with enhanced efficiency
    • Increasing adoption of TEO devices
  • Market Challenges
    • Stringent regulatory procedures for product commercialization

Porter's Five Forces: A Strategic Tool for Navigating the Transcatheter Embolization & Occlusion Device Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Transcatheter Embolization & Occlusion Device Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Transcatheter Embolization & Occlusion Device Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Transcatheter Embolization & Occlusion Device Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Transcatheter Embolization & Occlusion Device Market

A detailed market share analysis in the Transcatheter Embolization & Occlusion Device Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Transcatheter Embolization & Occlusion Device Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Transcatheter Embolization & Occlusion Device Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Transcatheter Embolization & Occlusion Device Market

A strategic analysis of the Transcatheter Embolization & Occlusion Device Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Transcatheter Embolization & Occlusion Device Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies Inc, Artio Medical, Inc., Becton Dickinson and Company, Boston Scientific Corporation, Edwards Lifesciences Corporation, Integer Holdings Corporation, Koninklijke Philips N.V., Medtronic PLC, Merit Medical Systems, Inc., Penumbra, Inc., Pfizer Inc., Sanofi SA, Siemens AG, Stryker Corporation, Terumo Corporation, and The 3M Company.

Market Segmentation & Coverage

This research report categorizes the Transcatheter Embolization & Occlusion Device Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Accessories, Embolization Coils, Embolization Particles, Flow Diverter Devices, and Liquid Embolics.
  • Based on Application, market is studied across Neurology, Oncology, Peripheral Vascular Disease, and Urology.
  • Based on End User, market is studied across Ambulatory Surgical Centers, Clinics, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing demand for minimally invasive surgeries
      • 5.1.1.2. Increased burden of targeted diseases
      • 5.1.1.3. Surge in incidence of cardiovascular diseases and respiratory disorders
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of products
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advances in the devices with enhanced efficiency
      • 5.1.3.2. Increasing adoption of TEO devices
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory procedures for product commercialization
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Transcatheter Embolization & Occlusion Device Market, by Product

  • 6.1. Introduction
  • 6.2. Accessories
  • 6.3. Embolization Coils
  • 6.4. Embolization Particles
  • 6.5. Flow Diverter Devices
  • 6.6. Liquid Embolics

7. Transcatheter Embolization & Occlusion Device Market, by Application

  • 7.1. Introduction
  • 7.2. Neurology
  • 7.3. Oncology
  • 7.4. Peripheral Vascular Disease
  • 7.5. Urology

8. Transcatheter Embolization & Occlusion Device Market, by End User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Clinics
  • 8.4. Hospitals

9. Americas Transcatheter Embolization & Occlusion Device Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Transcatheter Embolization & Occlusion Device Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Transcatheter Embolization & Occlusion Device Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Agilent Technologies Inc
  • 3. Artio Medical, Inc.
  • 4. Becton Dickinson and Company
  • 5. Boston Scientific Corporation
  • 6. Edwards Lifesciences Corporation
  • 7. Integer Holdings Corporation
  • 8. Koninklijke Philips N.V.
  • 9. Medtronic PLC
  • 10. Merit Medical Systems, Inc.
  • 11. Penumbra, Inc.
  • 12. Pfizer Inc.
  • 13. Sanofi SA
  • 14. Siemens AG
  • 15. Stryker Corporation
  • 16. Terumo Corporation
  • 17. The 3M Company
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦